Papaluca, T., Roberts, S. K., Strasser, S. I., Stuart, K. A., Farrell, G., MacQuillan, G., Dore, G. J., Wade, A. J., George, J., Hazeldine, S., O'Beirne, J., Wigg, A., Fisher, L., McGarity, B., Sawhney, R., Sinclair, M., Thomas, J., Valiozis, I., Weltman, M., Wilson, M., Woodward, A., Ahlenstiel, G., Haque, M., Levy, M., Prewett, E., Sievert, W., Sood, S., Tse, E., Valaydon, Z., Bowden, S., Douglas, M., New, K., O'Keefe, J., Hellard, M., Doyle, J., Stoove, M., & Thompson, A. J. (2021). efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. Clinical infectious diseases, 73, e3288–e3295. http://access.bl.uk/ark:/81055/vdc_100145633808.0x00001f